Država: Velika Britanija
Jezik: engleski
Izvor: myHealthbox
venlafaxine (as hydrochloride)
UK_ Milpharm Limited
NO6AX16
venlafaxine (as hydrochloride)
150mg
Prolonged-release tablet, hard
Oral use
7, 10, 14, 20, 28, 30, 50, 56, 60, 90, 98 and 100 capsules
POM - Prescription Only Medicine
APL Swift Services (Malta) Limited
Antidepressants, Other antidepressants
Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. Treatment of panic disorder, with or without agoraphobia.
Authorised
2015-01-23
Black VENZIP XL prolonged-release capsules, hard P150XXXX 9596 VENZIP XL prolonged-release capsules, hard P150XXXX 9596 PACKAGE LEAFLET : INFORMATION FOR THE USER VENZIP XL 75 MG PROLONGED-RELEASE CAPSULES, HARD VENZIP XL 150 MG PROLONGED-RELEASE CAPSULES, HARD Venlafaxine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What VENZIP XL is and what it is used for 2. What you need to know before you take VENZIP XL 3. How to take VENZIP XL 4. Possible side effects 5. How to store VENZIP XL 6. Contents of the pack and other information 1. WHAT VENZIP XL IS AND WHAT IT IS USED FOR VENZIP XL is an antidepressant that belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions such as anxiety disorders. It is thought that people who are depressed and/or anxious have lower levels of serotonin and noradrenaline in the brain. It is not fully understood how antidepressants work, but they may help by increasing the levels of serotonin and noradrenaline in the brain. VENZIP XL is a treatment for adults with depression. It is also a treatment for adults with the following anxiety disorders: generalised anxiety disorder, social anxiety disorder (fear or avoidance of social situations) and panic disorder (panic attacks). Treating depression or anxiety disorders properly is important to help you get better. If it is not tre Pročitajte cijeli dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT VENZIP XL 150 mg prolonged-release capsules, hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release capsule contains 150 mg of venlafaxine (as hydrochloride). Excipient with known effect: Each capsule contains 174.3 mg sucrose. _ _ For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged-release capsule, hard White to off-white spherical to oval pellets filled in Empty hard gelatin capsule shell (size ‘0’) of Opaque Dark orange color cap and Opaque Dark orange color body imprinted with “E” on cap and “89” on the body with edible black ink. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. _ _ Treatment of panic disorder, with or without agoraphobia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Major depressive episodes _ The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted due to symptom severity, dose increases can be made at more frequent intervals, but not less than 4 days. Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained. Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly on a case-by-case basis. Longer- term treatment may also be appr Pročitajte cijeli dokument